| Peer-Reviewed

Atomoxetine Beyond ADHD: A Fact or Aritfact

Received: 10 July 2015     Accepted: 23 July 2015     Published: 6 August 2015
Views:       Downloads:
Abstract

Atomoxetine is FDA-approved in Attention-Deficit/Hyperactivity Disorder (ADHD) with demonstrable efficacy and reasonable tolerability. It is classically a selective norepinephrine reuptake inhibitor but data accrues suggestive of an attractive pharmacologic portfolio speaking to the idea of a pluripotent psychotropic agent beyond ADHD. Heaps of cases in the literature abound portraying a multitude of indications with variable level of evidence oscillating from strong to only flimsy. Here, we shed light on these uses and testing extant evidence.

Published in American Journal of Psychiatry and Neuroscience (Volume 3, Issue 5)
DOI 10.11648/j.ajpn.20150305.12
Page(s) 90-93
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2015. Published by Science Publishing Group

Keywords

Atomoxetine-Pharmacology-Clinical Uses-Off Label Uses

References
[1] Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26
[2] Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699-711
[3] Ding YS, Naganawa M, Gallezot JD et al. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD. Neuroimage. 2014;86:164-71
[4] Ludolph AG, Udvardi PT, Schaz U, et al. Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J Pharmacol. 2010;160(2):283-91
[5] Kobayashi T, Washiyama K, Ikeda K. Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxitine. Neuropsychopharmacology. 2010;35(7):1560-9
[6] Creighton CJ, Ramabadran K, Ciccone PE, et al. Synthesis and biological evaluation of the major metabolite of atomoxetine : elucidation of a partial kappa-opioid agonist effect. Bioorg Med Chem Lett. 2004;14(15):4083-5
[7] Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9):915-24
[8] Berigan TR. Atomoxetine used adjunctively with selective serotonin reuptake inhibitors to treat depression. Prim Care Companion J Clin Psychiatry. 2004;6(2):93-94
[9] Michelson D, Adler LA, Amsterdam JD, et al. Addition of atomoxetine for depression incompletely responsive to sertraline : a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(4):582-7
[10] Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75(5):448-55
[11] Ravindran LN, Kim DS, Letamendi AM, et al. A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol. 2009;29(6):561-4
[12] McElroy SL, Guerdjikova A, Kotwal R, et al. Atomoxetine in the treatment of binge-eating disorder : a randomized placebo-controlled trial. J Clin Psychiatry. 2007;68(3):390-8
[13] Ball MP, Warren KR, Feldman S, et al. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizphr Relat Psychoses. 2011;5(1):17-25
[14] Friedman JI, Carpenter D, Lu J, et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol. 2008;28(1):59-63
[15] Kelly DL, Buchanan RW, Boggs DL, et al. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry. 2009;70(4):518-25
[16] Naguy A, Al-Mutairi H. Add-on atomoxetine mitigated different symptom domains in a case of Early-onset schizophrenia. J Psychiatry. 2015;18:279
[17] Poyurovsky M, Fuchs C, Pashinian A, et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl). 2007;192(3):441-8
[18] Jancovic J. Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009;284(1-2):177-8
[19] Marsh L, Biglan K, Gerstenhaber M, et al. Atomoxetine for the treatment of executive dysfunction in Parkinson’s Disease : a pilot open-label study. Mov Disord. 2009;24(2):277-82
[20] Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009;29(5):484-7
[21] Mohs RC, Shiovitz TM, Tariot PN, et al. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease : 6-month, randomized, double-blind, placebo-controlled, parallel trial study. Am J Geriatr Psychiatry. 2009;17(9):752-9
[22] Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders : placebo-controlled cross-over pilot study. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1196-205
[23] Sumner CR, Schuh KJ, Sutton VK, et al. Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. J Child Adolesc Psychopharmacol. 2006;16(6):699-711
[24] Shatkin JP. Atomoxetine for the treatment of pediatric nocturnal enuresis. J Child Adolesc Psychopharmacol. 2004;14(3):443-7
[25] Clark N. Conventional Antipsychotic and clozapine-induced urinary incontinence. JCPNP. 2003;2(2).
Cite This Article
  • APA Style

    Ahmed Naguy, Ali Al-Tajali. (2015). Atomoxetine Beyond ADHD: A Fact or Aritfact. American Journal of Psychiatry and Neuroscience, 3(5), 90-93. https://doi.org/10.11648/j.ajpn.20150305.12

    Copy | Download

    ACS Style

    Ahmed Naguy; Ali Al-Tajali. Atomoxetine Beyond ADHD: A Fact or Aritfact. Am. J. Psychiatry Neurosci. 2015, 3(5), 90-93. doi: 10.11648/j.ajpn.20150305.12

    Copy | Download

    AMA Style

    Ahmed Naguy, Ali Al-Tajali. Atomoxetine Beyond ADHD: A Fact or Aritfact. Am J Psychiatry Neurosci. 2015;3(5):90-93. doi: 10.11648/j.ajpn.20150305.12

    Copy | Download

  • @article{10.11648/j.ajpn.20150305.12,
      author = {Ahmed Naguy and Ali Al-Tajali},
      title = {Atomoxetine Beyond ADHD: A Fact or Aritfact},
      journal = {American Journal of Psychiatry and Neuroscience},
      volume = {3},
      number = {5},
      pages = {90-93},
      doi = {10.11648/j.ajpn.20150305.12},
      url = {https://doi.org/10.11648/j.ajpn.20150305.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajpn.20150305.12},
      abstract = {Atomoxetine is FDA-approved in Attention-Deficit/Hyperactivity Disorder (ADHD) with demonstrable efficacy and reasonable tolerability. It is classically a selective norepinephrine reuptake inhibitor but data accrues suggestive of an attractive pharmacologic portfolio speaking to the idea of a pluripotent psychotropic agent beyond ADHD. Heaps of cases in the literature abound portraying a multitude of indications with variable level of evidence oscillating from strong to only flimsy. Here, we shed light on these uses and testing extant evidence.},
     year = {2015}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Atomoxetine Beyond ADHD: A Fact or Aritfact
    AU  - Ahmed Naguy
    AU  - Ali Al-Tajali
    Y1  - 2015/08/06
    PY  - 2015
    N1  - https://doi.org/10.11648/j.ajpn.20150305.12
    DO  - 10.11648/j.ajpn.20150305.12
    T2  - American Journal of Psychiatry and Neuroscience
    JF  - American Journal of Psychiatry and Neuroscience
    JO  - American Journal of Psychiatry and Neuroscience
    SP  - 90
    EP  - 93
    PB  - Science Publishing Group
    SN  - 2330-426X
    UR  - https://doi.org/10.11648/j.ajpn.20150305.12
    AB  - Atomoxetine is FDA-approved in Attention-Deficit/Hyperactivity Disorder (ADHD) with demonstrable efficacy and reasonable tolerability. It is classically a selective norepinephrine reuptake inhibitor but data accrues suggestive of an attractive pharmacologic portfolio speaking to the idea of a pluripotent psychotropic agent beyond ADHD. Heaps of cases in the literature abound portraying a multitude of indications with variable level of evidence oscillating from strong to only flimsy. Here, we shed light on these uses and testing extant evidence.
    VL  - 3
    IS  - 5
    ER  - 

    Copy | Download

Author Information
  • Al-Manara Centre for CAP, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait

  • General Adult Psychiatrist, Head of Neuromodulation Unit, KCMH, Shuwaikh, State of Kuwait

  • Sections